SUPPORTING INFECTIOUS DISEASE RESEARCH

Mycobacterium tuberculosis, Strain KT-0004

Catalog No. NR-43789

Product Description:

Mycobacterium tuberculosis (M. tuberculosis), strain KT-0004 was isolated in 2009 from a human in South Korea. Strain KT-0004 was deposited as an extensively drug-resistant (XDR) Beijing genotype strain with resistance to capreomycin, isoniazid, kanamycin, moxifloxacin, ofloxacin, pyrazinamide, rifampin and streptomycin. NR-43789 was produced by inoculation of the deposited material into Middlebrook 7H9 broth with ADC enrichment. Broth inoculum was added to Middlebrook 7H10 agar with OADC enrichment kolles, which were grown for 35 days at 37°C in an aerobic atmosphere with 5% CO₂ to produce this lot.

Lot: 70013969

Manufacturing Date: 23MAY2018

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis ¹		
Cellular morphology	Gram-positive rods	Gram-positive rods
21 days at 37°C in an aerobic atmosphere with		
5% CO ₂ on Middlebrook 7H10 agar with OADC		
enrichment		
Colony morphology	Report results	Irregular, slight peaked, undulate, rough and cream (Figure 1)
Growth rate	≥ 7 days	21 days
Growth at 26°C	Negative	Negative
Growth at 37°C	Positive	Positive
Acid-fast stain	Positive (red colonies)	Positive (red colonies)
Pigmentation in the dark (Scotochromogen)	Negative (no pigment)	Negative (no pigment)
Photoinduction for 1 hour (Photochromogen)	Negative (no pigment)	Negative (no pigment)
Nonchromogen (no pigment)	Positive (no pigment)	Positive (no pigment)
Biochemical tests		
Niacin production ²	Positive	Positive
Nitrate reduction	Positive	Positive
Antibiotic Susceptibility Profile		
Sensititre™ System ^{3,4}		
Amikacin	Report results	16 μg/mL
Cycloserine	Report results	64 μg/mL ^{5,6}
Ethambutol	Report results	8 μg/mL ⁷
Ethionamide	Report results	10 μg/mL ^{6,7,8}
Isoniazid	Report results	> 4 µg/mL
Kanamycin	Report results	40 μg/mL
Moxifloxacin	Report results	8 µg/mL ^{6,9}
Ofloxacin	Report results	32 µg/mL ^{6,10}
Para-aminosalicylic acid	Report results	> 64 µg/mL ⁷
Rifabutin	Report results	> 16 µg/mL ⁷
Rifampin	Report results	> 16 µg/mL
Streptomycin	Report results	2 μg/mL ^{6,7,11}
Genotypic Analysis		
Sequencing of Heat Shock Protein 65 gene	≥ 99% sequence identity to	100% sequence identity to
(~ 1620 base pairs)	<i>M. tuberculosis,</i> strain KT-0004 (GenBank: JLNT01000005.1)	<i>M. tuberculosis,</i> strain KT-0004 (GenBank: JLNT01000005.1) ¹²
Purity (post-freeze)		
Middlebrook 7H10 agar with OADC enrichment	Growth consistent with expected	Growth consistent with expected
32 days at 37°C in an aerobic atmosphere with 5% CO_2	colony morphology	colony morphology
Tryptic Soy agar 21 days at 37°C in an aerobic atmosphere with 5% CO ₂	Report results	Growth consistent with expected colony morphology

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

Certificate of Analysis for NR-43789

SUPPORTING INFECTIOUS DISEASE RESEARCH

TEST	SPECIFICATIONS	RESULTS
Viability (post-freeze)	Growth	Growth
21 days at 37°C in an aerobic atmosphere with 5% CO ₂		
on Middlebrook 7H10 agar with OADC enrichment		

¹Information on *Mycobacterium* testing is available from Ribón, W. "Biochemical Isolation and Identification of Mycobacteria." <u>Biochemical Testing</u>. (2012) Jose C. Jimenez-Lopez (Ed.), InTech, <u>http://www.intechopen.com/books/biochemical-testing/biochemical-isolation-and-identification-of-mycobacteria</u> and Lévy-Frébault, V. V. and F. Portaels. "Proposed Minimal Standards for the Genus *Mycobacterium* and for Description of New Slowly Growing *Mycobacterium* Species." Int. J. Syst. Bacteriol. 42 (1992): 315-323. PubMed: 1581193.

²All mycobacteria produce niacin but only *M. tuberculosis* accumulates it, resulting in a positive test for *M. tuberculosis*.

³Sensititre[™] System Mycobacterium tuberculosis MIC Plate, Thermo Scientific[™], catalog number MYCOTB

⁴Minimum Inhibitory Concentration (MIC); No Clinical & Laboratory Standards Institute (CLSI) interpretations of the Sensititre™ System data for *M. tuberculosis* are currently available.

⁵Two MICs were observed for cycloserine (32 µg/mL and 64 µg/mL) under identical test conditions. The highest MIC is being reported as the test result.
⁶Variability in the MIC result by the Sensititre™ method has been demonstrated [Lee, J., et al. "Sensititre MYCOTB MIC Plate for Testing *Mycobacterium tuberculosis* Susceptibility to First- and Second-Line Drugs." <u>Antimicrob. Agents Chemother.</u> 58 (2014): 11-18. PubMed: 24100497.], with the results for a single antibiotic typically within one doubling dilution.

⁷For ethambutol, ethionamide, para-aminosalicylic acid, rifabutin and streptomycin, the endpoint for these drugs is determined by the well with approximately 80% inhibition of growth compared to the positive control well with no drug.

⁸Two MICs were observed for ethionamide (5 μg/mL and 10 μg/mL) under identical test conditions. The highest MIC is being reported as the test result. ⁹Two MICs were observed for moxifloxacin (4 μg/mL and 8 μg/mL) under identical test conditions. The highest MIC is being reported as the test result. ¹⁰Two MICs were observed for ofloxacin (16 μg/mL and 32 μg/mL) under identical test conditions. The highest MIC is being reported as the test result. ¹¹Two MICs were observed for streptomycin (1 μg/mL and 22 μg/mL) under identical test conditions. The highest MIC is being reported as the test result. ¹¹Two MICs were observed for streptomycin (1 μg/mL and 2 μg/mL) under identical test conditions. The highest MIC is being reported as the test result. ¹²Also consistent with *M. africanum, M. bovis, M. canettii, M. caprae* and *M. microti*

Figure 1: Colony Morphology



/Heather Couch/ Heather Couch

Program Manager or designee, ATCC Federal Solutions

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

Support Provided by NIAID

23 JUL 2020